(CALGB 10701) A Phase II Study Of Dasatinib (Sprycel) (IND #73969, NSC #732517) As Primary Therapy Followed by Transplantation For Adults >/= 50 Years With Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG, and SWOG

This study will study patients with acute lymphoblastic leukemia (ALL) with an abnormal chromosome feature known as the Philadelphia Chromosome. Patients diagnosed with ALL with the abnormal Philadelphia chromosome are said to have Philadelphia chromosome positive ALL (abbreviated as Ph+ ALL).
Dasatinib has been approved by the Food and Drug Administration (FDA) for use in patients diagnosed with chronic myeloid leukemia (abbreviated as CML), another type of leukemia that has the abnormal Ph+ chromosome feature, and in patients with Ph+ ALL whose leukemia either has not responded to or has returned despite previous therapy. Its use in patients with newly diagnosed Ph+ ALL is experimental. The experimental portion of this research study involves the use of Dasatinib in combination with standard chemotherapy and transplantation treatments for Ph+ ALL. Dasatinib blocks the action of the abnormal chromosome feature, and its use inhibits the growth of leukemia cells.

Study Number: 

NCG 185210

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.